The large number of biologic drug patents in the United States has contributed to delays in biosimilar availability.
This is a preview of subscription content, access via your institution
Subscribe to Nature+
Get immediate online access to Nature and 55 other Nature journal
Subscribe to Journal
Get full journal access for 1 year
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Biosimilars in the United States: Competition, Savings, and Sustainability (IQVIA, 2020); https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/iqvia-institute-biosimilars-in-the-united-states.pdf
Ferris, L. K., Gellad, W. F. & Hernandez, I. JAMA Dermatol. 156, 1136–1138 (2020).
Compilation of CDER New Molecular Entity (NME) Drug and New Biologic Approvals (FDA, accessed 6 August 2021); https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=reportsSearch.process
Sarpatwari, A., Barenie, R. & Curfman, G. Clin. Pharmacol. Ther. 105, 92–100 (2019).
FDA approvals. Big Molecule Watch (accessed 29 December 2021); https://www.bigmoleculewatch.com/fda-approved-ablas/
Biosimilar approval status. Biosimilars Review and Report (accessed 23 December 2021); https://biosimilarsrr.com/us-biosimilar-filings/
Medicines (EMA, accessed 23 December 2021); https://www.ema.europa.eu/en/medicines
Overpatented, Overpriced: How Excessive Pharmaceutical Patenting is Extending Monopolies and Driving up Drug Prices (IMAK, 2018); https://www.i-mak.org/wp-content/uploads/2018/08/I-MAK-Overpatented-Overpriced-Report.pdf
Druedahl, L. C. et al. Nat. Biotechnol. 38, 1253–1256 (2020).
Van de Wiele, V. L., Kesselheim, A. S. & Sarpatwari, A. Health Aff. 40, 1198–1205 (2021).
Price, W. N. & Rai, A. K. Iowa Law Rev. 101, 1023–1063 (2016).
Drug Pricing and Pharmaceutical Patenting Practices (Congressional Research Service, 2020); https://fas.org/sgp/crs/misc/R46221.pdf
BPCIA Litigations (Big Molecule Watch, accessed 13 May 2021); https://www.bigmoleculewatch.com/bpcia-patent-litigations/
Patent Term Calculator (USPTO, accessed 6 August 2021); https://www.uspto.gov/patents/laws/patent-term-calculator
Beall, R. F., Darrow, J. J. & Kesselheim, A. S. Value Health 21, 1382–1389 (2018).
Vilcek, J. Nat. Immunol. 10, 555–557 (2009).
Pelechas, E., Voulgari, P. V. & Drosos, A. A. Expert Opin. Drug Discov. 16, 227–234 (2021).
Hemphill, C. S. & Sampat, B. Science 339, 1386–1387 (2013).
Rai, A. K. & Price, W. N. II Nat. Biotechnol. 39, 20–22 (2021).
Bergman, M., Patel, P., Chen, N., Jing, Y. & Saffore, C. D. Rheumatol. Ther. 8, 109–118 (2021).
Chung, A. Europe issues better patents than US – Europe patent boss. Reuters (15 September 2016).
Picard, P. M. & van Pottelsberghe de la Portterie, B. J. Public Econ. 104, 14–25 (2013).
Moorkens, E., Vulto, A. G. & Huys, I. MAbs 12, 1743517 (2020).
Feldman, R. Drugs, Money, and Secret Handshakes (Cambridge Univ. Press, 2019).
Bloomfield, D. & Kesselheim, A.S. Biden can lower drug prices without Congress doing anything. Washington Post (5 January 2021).
Frakes, M.D. & Wasserman, M.F. Investing in Ex Ante Regulation: Evidence from Pharmaceutical Patent Examination (NBER, 2020); https://www.nber.org/papers/w27579
This work was supported by Arnold Ventures.
The authors declare no competing interests.
About this article
Cite this article
Van de Wiele, V.L., Beall, R.F., Kesselheim, A.S. et al. The characteristics of patents impacting availability of biosimilars. Nat Biotechnol 40, 22–25 (2022). https://doi.org/10.1038/s41587-021-01170-5